Intravenous immunoglobulin for myasthenia gravis
Record ID 32013000178
English
Authors' recommendations:
Intravenous immunoglobulin (IVIG) has been investigated as a treatment for a variety of neurological disorders, including myasthenia gravis (MG). The goal of IVIG for neurological disorders is to eliminate or reduce neurologic symptoms and normalize or improve neurologic function by enhancing immune capability with components that substitute for immune deficiencies, improve the modulation of inflammatory processes, or allow the destruction of autoantibodies.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=1985
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Immunoglobulins, Intravenous
- Myasthenia Gravis
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.